Experience real-time quotes, in-depth charts, and analyst ratings

MARKET

GILD

Gilead Sciences Inc

NASDAQ

66.35

+0.19

+0.29%

Opening 13:52 04/19 EDT

OPEN

66.36

PREV CLOSE

66.16

HIGH

66.72

LOW

66.16

VOLUME

3.77M

TURNOVER

52 WEEK HIGH

87.87

52 WEEK LOW

65.90

MARKET CAP

82.74B

P/E (TTM)

14.73

Gilead Sciences Is Maintained at Outperform by Oppenheimer

Dow Jones · 11h ago

Gilead Sciences Price Target Maintained With a $105.00/Share by Oppenheimer

Dow Jones · 11h ago

Oppenheimer Maintains Outperform on Gilead Sciences, Maintains $105 Price Target

Benzinga · 11h ago

FDA Mandates "Boxed Warning" For Bristol Myers, Johnson & Johnson CAR-T-Based Blood Cancer Therapies

The FDA said on Thursday it will require boxed warnings for all CAR-T cancer therapies. The blood cancer treatments may pose a risk of secondary cancers, the agency said. In November, the FDA announced it was investigating reports of patients developing T-cell malignancies. The agency asked drugmakers to add a boxed warning to the products in January.

Benzinga · 12h ago

Analysts Are Bullish on These Healthcare Stocks: Gilead Sciences (GILD), Biogen (BIIB)

TipRanks · 14h ago

GILEAD <GILD.O>: BMO CUTS TARGET PRICE TO $80 FROM $89

Reuters · 15h ago

FDA requires labeling changes to CAR-T cell therapies to reflect cancer risk

FDA requires labeling changes to CAR-T cell therapies to reflect cancer risk. New class of cancer treatments will require updates to their safety information to indicate a severe risk of secondary malignancies. The issue relates to a new class of CAR T cell therapies, the FDA says.

Seeking Alpha · 16h ago

U.S. RESEARCH ROUNDUP-Blackstone, Ellington Financial, Netflix

Wall Street analysts revise their ratings and price targets on several U.S.-listed companies. Blackstone, Ellington Financial and Netflix among companies with revised targets. Coca-Cola, AIG and Berkshire Hathaway among those with target price increases. Some analysts cut their target prices on the companies.

Reuters · 18h ago

About GILD

Gilead Sciences, Inc. is a biopharmaceutical company. It is engaged in advancing medicines to prevent and treat life-threatening diseases, including human immunodeficiency virus (HIV), viral hepatitis, coronavirus disease 2019 (COVID-19) and cancer. It is focused on the discovery, development and commercialization of medicines in areas of unmet medical need. Its portfolio of marketed products includes AmBisome, Atripla, Biktarvy, Cayston, Complera, Descovy, Descovy for PrEP, Emtriva, Epclusa, Eviplera, Genvoya, Harvoni, Hepcludex, Hepsera, Jyseleca, Letairis, Odefsey, Sovaldi, Stribild, Sunlenca, Tecartus, Trodelvy, Truvada, Truvada for PrEP, Tybost, Veklury, Vemlidy, Viread, Vosevi, Yescarta and Zydelig. Its product candidates include Bulevirtide, Lenacapavir, Axicabtagene ciloleucel, and Domvanalimab and zimberelimab, and seladelpar. Seladelpar shall be used for the treatment of primary biliary cholangitis (PBC), including pruritus. The Company operates in more than 35 countries.

Webull offers Gilead Sciences, Inc. stock information, including NASDAQ: GILD real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, GILD stock news, and many more online research tools to help you make informed decisions. Trade stocks for 0 commission and 0 contract fees on the web version for easy and convenient access, or download the Webull app and trade on the go.

You can practice and explore trading GILD stock methods without spending real money on the virtual paper trading platform.